title: Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
authors.affiliation: VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: Hans M
authors.initials: HM
authors.lastname: Westgeest
authors.forename: Nielka P
authors.initials: NP
authors.lastname: van Erp
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Honeywell
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoekstra
authors.forename: Godefridus J
authors.initials: GJ
authors.lastname: Peters
authors.forename: Henk M W
authors.initials: HM
authors.lastname: Verheul
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects*; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib